• Fresh campaign highlights Cooper Kupp’s experience with eye allergies and how Pataday can provide itch relief for millions of Americans with eye allergies1
  • Partnership supports Pataday Once Daily Relief Extra Strength, the first 24-hour eye allergy itch relief drop available without a prescription in the U.S.2
  • Multimedia program motivates consumers to add Pataday eye allergy drops to their allergy routine for targeted eye itch relief

FORT WORTH, Texas–(BUSINESS WIRE)–Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a partnership with Cooper Kupp, professional football wide receiver and MVP of the “Big Game,” to share his experience with eye allergies and help other eye allergy sufferers find relief with Pataday® Once Daily Relief Extra Strength. This year’s campaign, The Right Tool for the Job, highlights Kupp’s personal struggle to find the right product to treat his eye allergy symptoms and how Pataday has delivered fast-acting, long-lasting, and targeted relief for his itchy allergy eyes on and off the field.

“When the seasons change, which, unfortunately, coincides with spring organized team activities (OTAs) and the dog days of training camp, my allergies flare up. In those weeks, when we’re outdoors working out, the pollen can really make my eyes itch and distract me from focusing on the small but crucial details of my work,” said Kupp. “I use PatadayOnce Daily Relief Extra Strength because it puts me in control of my allergy symptoms and it’s efficient. With just one drop in each eye, I love that I can count on 24 hours of relief from itchy eyes.”

Pataday is the #1 doctor-recommended eye allergy itch relief drop brand and is available without a prescription.3 As an antihistamine eye drop, the product works right on the cells that make your eyes itch.2 To highlight key product benefits and encourage consumers to consider Pataday as The Right Tool for the Job of treating itchy allergy eyes, a full-scale media campaign will run in 2022, including organic and paid social content; partnerships with social media influencers detailing their experiences with eye allergies; and a drive for consumers to learn more about and try Pataday Once Daily Relief Extra Strength.

“Alcon is thrilled to welcome Cooper Kupp to the Pataday team as a consumer advocate for an important, but often overlooked, allergy patient need,” said Harvey Brown Jr., Senior Director, Dry Eye and Ocular Health at Alcon. “Approximately 66 million Americans suffer from ocular allergies, but only 9 million use an over-the-counter allergy eye drop to relieve their symptoms.4-7 Through this campaign, we hope to encourage eye allergy sufferers to find targeted, fast-acting relief from their eye allergy symptoms.”

Pataday Once Daily Relief Extra Strength is available in the U.S. in drug, mass and grocery stores, as well as online retailers. Alcon’s Pataday portfolio of products offers fast, long-lasting eye allergy itch relief to the U.S. population affected by allergic conjunctivitis.2 Pataday Once Daily Relief Extra Strength provides a full 24 hours of eye allergy itch relief from pollen, ragweed, grass, and animal hair and dander for people ages two and older with just one drop once a day.2

For more information, visit Pataday.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

References

  1. U.S. Census Bureau. 2019.
  2. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016.
  3. Based on IQVIA ProVoice Survey of Physicians and Optometrists 12 months ending December 31, 2021.
  4. U.S. Census Bureau (2014). US CENSUS BUREAU – Projections of the Population by Sex and Age for the United States – 2015 to 2060.
  5. Singh, K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994.
  6. U.S. Population Census 2019. 6. Nielsen Household Panel Data Feb. 2019.
  7. Nielsen Latest 52 weeks 2/6/2019.

Connect with us on

Facebook
LinkedIn

Contacts

Media Relations

Wes Warnock  

+ 41 589 112 111 (Geneva) 

+ 1 817 615 2501 (Fort Worth)

globalmedia.relations@alcon.com

Investor Relations 

Allen Trang

+ 41 589 112 110 (Geneva) 

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com

Author

Comments are closed.

Get our e-letters packed with news and intelligence!